Download presentation
Presentation is loading. Please wait.
1
Skeletal muscle relaxants
Prof. Hanan Hagar
2
By the end of this lecture, students should be able to:
Learning objectives By the end of this lecture, students should be able to: Identify classification of skeletal muscle relaxants Describe the pharmacokinetics and dynamics of neuromuscular relaxants Recognize the clinical applications for neuromuscular blockers Know the different types of spasmolytics Describe the pharmacokinetics and dynamics of spasmolytic drugs Recognize the clinical applications for spasmolytic drugs
3
Skeletal muscle relaxants
Are drugs used to induce muscle relaxation Classification Peripherally acting (Neuromuscular blockers). Centrally acting skeletal muscle relaxants e.g. Baclofen - Diazepam Direct acting skeletal muscle relaxants e.g. Dantrolene
4
Peripheral acting sk. M. relaxants Neuromuscular blockers
These drugs act by blocking neuromuscular junction or motor end plat leading to skeletal muscle relaxation.
5
Neuromuscular blockers
Classification: 1) Competitive (non depolarizing blockers) 2) Depolarizing blockers
6
Competitive NM blockers
Mechanism of Action Are competitive antagonists Compete with Ach for the nicotinic receptors present in post-junctional membrane of motor end plate. No depolarization of post-junctional membrane
8
Neuromuscular Junction
9
Competitive NM blockers
Have the suffix curium or curonium Classified according to duration of action into: Long acting d-tubocurarine (proto type drug) Pancuronium
10
Competitive NM blockers
Intermediate acting Atracurium Cisatracurium Vecuronium Rocuronium Short acting Mivacurium
11
Pharmacokinetics of competitive NM blockers
They are polar compounds inactive orally & taken parenterally Do not cross BBB (no central action) Do not cross placenta Metabolism depend upon kidney or liver Except Mivacurium (degraded by acetylcholinesterase ) Atracurium (spontaneous degradation in blood)
12
Pharmacological actions of competitive NMBs:
Skeletal muscle relaxation. They produce different effects on CVS Some release histamine and produce hypotension d.Tubocurarine Atracurium Mivacurium Others produce tachycardia ( H.R) Pancuronium
13
d – Tubocurarine Long duration of action (1 - 2 hr)
Eliminated by kidney 60% - liver 40%. Releases histamine that causes: Bronchospasm (constriction of bronchial smooth muscles). Hypotension Tachycardia
14
Atracurium As potent as curare
Has intermediate duration of action (30 min). Liberate histamine (Transient hypotension) Eliminated by non enzymatic chemical degradation in plasma (spontaneous hydrolysis at body pH, Hofmann elimination). used in liver failure & kidney failure (drug of choice).
15
Mivacurium Chemically related to atracurium Fast onset of action
Short duration of action (15 min). Metabolized by pseudo-cholinesterases. Longer duration in patient with liver disease or genetic cholinesterase deficiency or malnutrition. Transient hypotension (due to histamine release).
16
Pancuronium Excreted by the kidney ( 80 % ). Long duration of action.
More potent than curare (6 times). Excreted by the kidney ( 80 % ). Long duration of action. Side effects : Hypertension, tachycardia NE release from adrenergic nerve endings. Antimuscarinic action (block parasympathetic action)
17
Vecuronium More potent than tubocurarine ( 6 times ).
Metabolized mainly by liver. Intermediate duration of action. Has few side effects. No histamine release. No tachycardia.
18
Depolarizing Neuromuscular Blockers
Mechanism of Action combine with nicotinic receptors in post-junctional membrane of neuromuscular junction initial depolarization of motor end plate muscle twitching persistent depolarization relaxation
19
Succinylcholine (suxamethonium)
Pharmacological Actions SK. muscle : initial contraction followed by relaxation. Hyperkalemia : Cardiac arrest. Eye : intraocular pressure. CVS : arrhythmia
20
Pharmacokinetics Fast onset of action (1 min.). Short duration of action (5-10 min.). Metabolized by pseudo-cholinesterase in plasma Half life is prolonged in Neonates Elderly Pseudo-cholinesterase deficiency (liver disease or malnutrition or genetic cholinesterase deficiency).
21
Side Effects Hyperkalemia CVS arrhythmia Intraocular pressure contraindicated in glaucoma Can produce malignant hyperthermia May cause succinylcholine apnea due to deficiency of pseudo-cholinesterase.
22
Malignant hyperthermia
Is a rare inherited condition that occurs upon administration of drugs as: general anesthesia e.g. halothane neuromuscular blockers e.g. succinylcholine Inability to bind calcium by sarcoplasmic reticulum in some patients due to genetic defect. Ca release, intense muscle spasm, hyperthermia
23
Notes Side effects Duration Drug Tubocurarine Pancuronium Atracurium
# Renal failure Hypotension Long 1-2 h Tubocurarine # Renal failure Tachycardia Pancuronium Spontaneous degradation Used in liver and kidney failure Transient hypotension Histamine release Short 30 min. Atracurium # Liver failure Few side effects 40 min. Vecuronium Metabolized by pseudocholinesterase # Choline esterase deficiency Similar to atracurium 15 min. Mivacurium # CVS Diseases # Glaucoma # Liver disease Hyperkalemia Arrhythmia Increase IOP 10 min. Succinyl choline
26
Uses of neuromuscular blockers
control convulsion electroshock therapy in psychotic patient . Relieve of tetanus and epileptic convulsion. As adjuvant in general anesthesia to induce muscle relaxation Facilitate endotracheal intubation Orthopedic surgery.
27
Spasmolytics These drugs reduce muscle spasm produced by neurological disorders. Classification Centrally acting skeletal muscle relaxants e.g. Baclofen – Diazepam Direct acting skeletal muscle relaxants e.g. Dantrolene
28
Central acting skeletal muscle relaxants
Baclofen: Centrally acting GABA agonist – acts on spinal cord. Diazepam (Benzodiazepines): facilitate GABA action on CNS.
29
Dantrolene Mechanism of Action
It interferes with the release of calcium from its stores in skeletal muscles (sarcoplasmic reticulum). It inhibits excitation-contraction coupling in the muscle fiber. Orally, IV, (t ½ = hrs). Uses Malignant Hyperthermia. Spastic states.
30
Uses of spasmolytics They reduce muscle spasm in spastic states produced by : Spinal cord injury Cerebral stroke Cerebral palsy
31
Alteration of responses
Increase in duration of action of skeletal muscle relaxants by diseases as: Diseases Myasthenia gravis Kidney failure Liver failure
32
Alteration of responses
Increase in duration of action of skeletal muscle relaxants by drugs as: Drug interactions General anesthetics Aminoglycosides antibiotics ( e.g. gentamycin) Anticonvulsants Magnesium
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.